Physician Calls for Equal Provincial Funding for Shingles Vaccine in Canada

Dr. Marla Shapiro is calling for equal provincial funding for the shingles vaccine across Canada to increase uptake and ensure equitable access.

This push for funding addresses a gap in public health coverage that leaves many Canadians unable to afford protection against a virus known for severe complications. Because funding varies by province, access to the vaccine remains inconsistent across the country.

Shapiro said the vaccine is currently underutilized despite its potential to prevent shingles and its associated health risks. The vaccine does more than prevent the painful rash associated with shingles; it may also reduce the risk of heart disease, stroke, and dementia [1, 2, 3].

Public health officials and doctors are monitoring how these preventative measures impact long-term wellness. Shingrix, the vaccine in question, received FDA approval in 2017 ^[4]. While the vaccine is available, the cost remains a barrier for many citizens in provinces where the government does not provide full funding.

There is ongoing debate regarding the cost-effectiveness of providing the vaccine through public health systems. Some reports from Ireland suggest the vaccine is not cost-effective for public provision ^[5]. However, other data suggests the vaccine may dramatically reduce heart attacks, strokes, and death, which implies significant health-economic benefits for the state ^[2].

Shapiro said that providing equal funding across all provinces would reduce the overall burden of shingles cases and the severe complications that follow. By removing the financial barrier, Canada could see a decrease in hospitalizations related to shingles-induced complications. The goal is to move toward a system where a patient's postal code does not determine their ability to prevent a debilitating illness.